NEW YORK (360Dx) – Each year more Americans die from sepsis in the hospital than from any other cause.

To address this, a bolus of companies over the past year have plunged into the market, developing rapid tests to identify the condition that kills about 300,000 Americans each year. In December, Nanomix joined the mix, announcing it is developing a point-of-care test leveraging an electrochemical biosensor platform and enzyme- and immune-based assays to simultaneously probe for three biomarkers.